原文开头
Studies probe the limits of new sodium channel blockers JENNIE ERIN SMITH I n the past decade, as opioids claimed nearly half a million lives across the United States, surgeons, dentists, and other clinicians have pined for pain relievers that work as well as hydrocodone or oxycodone but without the high risk of addiction and overdose. Last year, the U.S. Food and Drug Administration (FDA) approved suzetrigine, the first in a new class of drugs that promised pain relief approaching that of opioid pills without those concerns. Although both Nav1.7 and Nav1.8 showed promise as drug targets in lab studies, clinical research has pointed to the latter as the stronger bet. …
摘自《科学》(Science)第393卷 第6812期 · 2026年8月13日,Jennie Erin Smith。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。